We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment ...

In the U.S., Niktimvo will be co-commercialized by Syndax and Incyte. The Company announced Niktimvo was added to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.